Medical Screening

Cardiovascular Health

Regular price
$239.00
Regular price
Sale price
$239.00

Personalized genetic insights to help you find the right heart medications

Inagene’s new cardiology test offers personalized genetic insights into how your body responds to critical heart medications.

Medications screened

We screen for 49 of the most prescribed medications to treat high cholesterol, blood thinning, direct heart treatment, and more.

Search Medications

Shipping information

Canada & US: Free shipping on your order and free return shipping for your swab. A prepaid return label is included in your package.

International: Free shipping to you but return shipping for your swab is not included.

Cardiovascular Health
Cardiovascular Health
Cardiovascular Health
Cardiovascular Health

Powerful genetic insights

We use the world’s best science to help you limit trial and error, avoid side effects, and find the right medications faster. 

Prevent heart attacks and strokes

Optimize critical medications for cholesterol, blood thinning and heart function to help prevent serious cardiovascular events with the best dose and medication tailored to your genetics.

Avoid side effects

By understanding your unique genetic profile you can avoid unnecessary side effects and improve the effectiveness of prescribed medications. Pharmacogenetic testing can help reduce the risk of side effects by 30%.¹

Are statins right for you?

12% of Canadians aged 20-79² have reported taking statins, yet as many as 40% of older adults stop taking statins within two years³, often due to side effects like muscle pain.

Case Study:

  • A commonly prescribed blood thinner

  • Clopidogrel, known as Plavix in many countries, is a commonly prescribed blood thinner for preventing recurrent strokes and heart attacks. Research has consistently shown that a specific gene (known as CYP2C19) significantly influences the drug's effectiveness. Everyone has two versions of this gene, and the combination, or "phenotype" of these versions, determines the drug's efficacy.

Pharmacogenetic testing has found these cases in which clopidogrel is not likely to be effective:

  • 39%

    of individuals of African American/Afro-Caribbean

  • 23%

    of individuals of American

  • 49%

    of individuals of Central or South Asian descent

  • 59%

    of East Asian descent

  • 29%

    of individuals of European descent

  • 21%

    of individuals of Latino descent

  • 25%

    of individuals of Near Eastern descent

  • 39%

    of individual of Sub-Saharan African descent

  • 94%

    of individuals of Oceanian descent

If clopidogrel is ineffective, it significantly increases the risk of recurrent strokes or heart attacks, highlighting the importance of pharmacogenetic testing for personalized medication management.

How It Works

It starts with a simple cheek
swab test at home

  • Swab your cheek with our kit and mail it to our lab with the package provided.

  • When your results are ready, view and download your personalized insights report.

  • Discuss your results with your healthcare provider to optimize your treatment plan.

The Inagene report

Your Inagene report is a personalized guide on how your genetic information affects your body’s needs. It delivers clear recommendations so you can make informed personal health decisions, avoid trial and error, prevent side effects, and find effective medications faster. The report places medications into four categories, based on the detection of specific genetic variants known to impact individual responses to drugs:

  • Consider Alternatives

    Genetic variant(s) potentially impacting response to this medication were identified. This medication may not be appropriate. Consult the “detailed recommendations” section of the report for details.

  • Use With Caution

    Genetic variant(s) potentially impacting response to this medication were identified. Consult the “detailed recommendations” section of the report for details.

  • Use As Directed

    No genetic variants impacting response to this medication were identified.

  • Use As Directed/Preferred

    Genetic variant(s) potentially improving response to this medication were identified. Consult the “detailed recommendations” section of the report for details.

See a sample report

Your privacy is our top priority

  • Secure Data Handling

  • Strict Confidentiality 

  • Accredited Laboratory 

  • Transparent Practices

FAQ

Which diseases/conditions does the test cover?

Your Inagene Report doesn’t provide disease risk information, but rather describes your unique predicted response to medications commonly used to treat a variety conditions (eg. Anesthesia, Cardiology, Endocrinology, Gastroenterology, Immunology, Infectious Disease, Neurology, Oncology, Respirology and Urology). The results are specific to individual medications (not health conditions), so the recommendations apply regardless of what type of pain, mental health, or other health conditions the drug is being used to treat.

What can Inagene reveal about my treatment strategy?

Your Inagene report offers guidance on which drugs are likely to work best for you, and which you should avoid – based on increased risk of side effects or drug interactions – so you and your healthcare team can manage your health concerns as effectively and safely as possible. The reports are available on our secure portal so that you can easily share your reports with others.

Where do the recommendations in the report come from?

The recommendations in Inagene’s report are backed by published, publicly available pharmacogenetic recommendations from several well-recognized, government-funded governing bodies that have been established over the past two decades in the USA, Europe, and Asia. We pair this science and expertise with the insights gleaned from your DNA profile to provide you with personalized insights you can trust.

  • References

    1. Swen JJ, van der Wouden CH, Manson LE, et al.
    2. Statistics Canada
    3. Swen JJ, van der Wouden CH, Manson LE, et al.
    4. Lee CR, Luzum JA, Sangkuhl K, et al.